arsenic trioxide has been researched along with Cancer of Cervix in 25 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 12 (48.00) | 29.6817 |
2010's | 11 (44.00) | 24.3611 |
2020's | 2 (8.00) | 2.80 |
Authors | Studies |
---|---|
He, ZY; Li, DC; Li, HY; Li, SJ; Liang, ZZ; Yan, J | 1 |
He, Z; Huang, J; Li, D; Li, H; Pan, D; Yang, H; Zhang, Y | 1 |
Akhtar, A; Bell, C; Ghali, L; Wang, SX; Wen, X | 1 |
Akhtar, A; Bell, C; Ghali, L; Li, D; Wang, SX; Wen, X | 1 |
Chang, YW; Chen, CA; Chen, MW; Cheng, CC; Chiu, CF; Hong, CC; Hsiao, M; Su, JL; Wei, LH | 1 |
Gao, P; Wang, H; Zheng, J | 1 |
Chang, HR; Lu, FJ; Ting, HC; Tsai, ML; Yen, CC | 1 |
Kang, YH; Lee, SJ | 2 |
Chung, WH; Kim, SS; Kuh, HJ; Rhim, H; Sung, BH | 1 |
Lin, F; Long, M; Ren, JH; Wang, X; Wei, JX; Yan, L; Zhang, HZ | 1 |
Duru, N; Guo, Q; He, G; Kong, X; Li, JJ; Sui, L; Wan, B; Wang, L; Wang, Q; Wu, X; Yu, L; Zhang, P; Zhou, Y | 1 |
Li, A; Shen, L; Xu, W; Ye, J; Zhou, J | 1 |
Ghali, L; Iles, RK; Li, D; Liu, S; Wen, X; Zhang, Y | 1 |
Ahn, WS; Bae, SM; Bang, HJ; Battogtokh, G; Kim, YW | 1 |
Byun, JM; Jeong, DH; Kang, MS; Kim, JR; Kim, KT; Kim, YN; Lee, DS; Lee, KB; Park, SG; Sung, MS | 1 |
Kim, EJ; Lee, SY; Myoung, J; Namkoong, SE; Park, JS; Um, SJ | 1 |
Ahn, WS; Bae, SM; Kim, CK; Kim, YW; Lee, IP; Lee, JM; Lee, KH; Namkoong, SE; Seo, JS; Sin, JI | 1 |
An, S; Cho, H; Gwak, HS; Hong, SI; Hong, YJ; Jin, HO; Lee, HC; Lee, SJ; Park, IC; Park, MJ; Park, SA; Rhee, CH; Woo, SH | 1 |
Fu, M; Li, Y; Liang, X; Lin, C; Qian, H; Wang, Y; Yu, J; Zhang, X | 2 |
Cheson, BD; McBee, WL; Murgo, AJ | 1 |
Du, YH; Ho, PC | 1 |
Chen, J; Deng, Y; Fu, M; Liang, X; Lin, C; Wu, M; Xiao, P; Zheng, J | 1 |
Chun, YJ; Chung, HY; Hong, SI; Kim, TH; Lee, SJ; Lee, YS; Park, IC; Park, MJ; Rhee, CH; Woo, SH | 1 |
1 trial(s) available for arsenic trioxide and Cancer of Cervix
Article | Year |
---|---|
A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Platinum; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; Uterine Cervical Neoplasms | 2022 |
24 other study(ies) available for arsenic trioxide and Cancer of Cervix
Article | Year |
---|---|
Effects of arsenic trioxide combined with platinum drugs in treatment of cervical cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Meta-Analysis as Topic; Platinum Compounds; Randomized Controlled Trials as Topic; Research Design; Systematic Reviews as Topic; Uterine Cervical Neoplasms | 2020 |
Effective Delivery of Arsenic Trioxide to HPV-Positive Cervical Cancer Cells Using Optimised Liposomes: A Size and Charge Study.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Drug Compounding; Drug Delivery Systems; Female; Humans; Liposomes; Oxides; Papillomavirus Infections; Particle Size; Static Electricity; Uterine Cervical Neoplasms | 2018 |
Optimisation of Folate-Mediated Liposomal Encapsulated Arsenic Trioxide for Treating HPV-Positive Cervical Cancer Cells In Vitro.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Female; Folic Acid; HeLa Cells; Humans; Liposomes; Papillomaviridae; Polyethylene Glycols; Uterine Cervical Neoplasms | 2019 |
Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-κB signaling in cervical cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Chemokine CXCL12; Down-Regulation; Female; HeLa Cells; Humans; Lung Neoplasms; Mice; MicroRNAs; Neoplasm Invasiveness; NF-kappa B; Oxides; Protein Phosphatase 2; Receptors, CXCR4; RNA, Messenger; Signal Transduction; Transcription, Genetic; Uterine Cervical Neoplasms | 2014 |
Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Female; HeLa Cells; Human papillomavirus 16; Humans; Oncogene Proteins, Viral; Oxides; Papillomavirus E7 Proteins; Papillomavirus Infections; Repressor Proteins; Retinoblastoma Protein; Transcription Factor AP-1; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2014 |
Environmentally relevant concentration of arsenic trioxide and humic acid promoted tumor progression of human cervical cancer cells: In vivo and in vitro studies.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Glutathione; HeLa Cells; Humans; Humic Substances; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred NOD; Mice, SCID; Mitosis; Oxides; Reactive Oxygen Species; Transplantation, Heterologous; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A | 2016 |
Role of p38 MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspases; Cell Nucleus; Combined Modality Therapy; Cytosol; Female; HeLa Cells; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinases; Membrane Potential, Mitochondrial; Mitochondria; Oxides; Phosphorylation; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation, Ionizing; Reactive Oxygen Species; Signal Transduction; Uterine Cervical Neoplasms | 2008 |
Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Cisplatin; Drug Interactions; Drug Synergism; Female; Fluorouracil; Head and Neck Neoplasms; Humans; In Vitro Techniques; Inhibitory Concentration 50; Oxides; Paclitaxel; Poly(ADP-ribose) Polymerases; Stomach Neoplasms; Tubulin; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2009 |
Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Female; HeLa Cells; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Stathmin; Survival Analysis; Tumor Burden; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2010 |
YY1 is a novel potential therapeutic target for the treatment of HPV infection-induced cervical cancer by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; DNA Primers; Female; HeLa Cells; Human papillomavirus 16; Humans; Oxides; Papillomavirus Infections; Polymerase Chain Reaction; RNA, Messenger; Uterine Cervical Neoplasms; YY1 Transcription Factor | 2011 |
JWA enhances As₂O₃-induced tubulin polymerization and apoptosis via p38 in HeLa and MCF-7 cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Female; Flow Cytometry; Gene Silencing; Growth Inhibitors; Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Membrane Transport Proteins; Microscopy, Fluorescence; Oxides; p38 Mitogen-Activated Protein Kinases; Plasmids; Polymerization; RNA, Small Interfering; Signal Transduction; Transfection; Tubulin; Tubulin Modulators; Up-Regulation; Uterine Cervical Neoplasms | 2011 |
Arsenic trioxide induces cervical cancer apoptosis, but specifically targets human papillomavirus-infected cell populations.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; HeLa Cells; Humans; Oncogene Proteins, Viral; Oxides; Papillomavirus Infections; Repressor Proteins; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2012 |
Synergistic anti-tumor effects of combination of photodynamic therapy and arsenic compound in cervical cancer cells: in vivo and in vitro studies.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Mice; Neoplasm Proteins; Neoplasms, Experimental; Oxides; Photochemotherapy; Uterine Cervical Neoplasms | 2012 |
Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; Female; Humans; Mice; Oxides; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA-Binding Proteins; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Neoplasm Invasiveness; Oncogene Proteins, Viral; Oxides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Transcription Factor AP-1; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2002 |
Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Cell Cycle; Cell Division; Cell Line, Tumor; DNA; DNA Fragmentation; DNA Repair; DNA, Complementary; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Oxides; RNA; Time Factors; Up-Regulation; Uterine Cervical Neoplasms | 2004 |
Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB activation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; fas Receptor; Female; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Oxides; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Up-Regulation; Uterine Cervical Neoplasms | 2004 |
Therapeutic effect of arsenic trioxide (As2O3) on cervical cancer in vitro and in vivo through apoptosis induction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 9; Cell Line, Tumor; Female; Humans; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; Microtubules; Mitochondria; Oxides; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2007 |
Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo.
Topics: Animals; Arsenic Trioxide; Arsenicals; beta Catenin; Cadherins; Caveolin 1; Cell Adhesion; Cell Line, Tumor; Cell Movement; Female; Growth Inhibitors; HeLa Cells; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Oxides; Uterine Cervical Neoplasms | 2007 |
The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Enzyme Activation; Female; HeLa Cells; Humans; MAP Kinase Kinase 4; Membrane Potential, Mitochondrial; Mitochondria; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Transfection; Uterine Cervical Neoplasms | 2008 |
Clinical trials referral resource. Clinical trials with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Female; Humans; Leukemia; Lymphoma; Multiple Myeloma; Neoplasms; Oxides; Urogenital Neoplasms; Uterine Cervical Neoplasms | 2000 |
Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Size; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; HeLa Cells; Humans; Ovarian Neoplasms; Oxides; Sulfides; Time Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2001 |
Overexpression of Bcl-2 partly inhibits apoptosis of human cervical cancer SiHa cells induced by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Cycle; Cell Survival; DNA, Neoplasm; Female; Humans; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2000 |
Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3).
Topics: Animals; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Evaluation, Preclinical; Female; HeLa Cells; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Oxides; Radiation-Sensitizing Agents; Treatment Outcome; Tumor Stem Cell Assay; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2002 |